



IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 18, 2004

Signature:

*Shawn P. Foley*  
(Shawn P. Foley)

Docket No.:  
CELLTH 3.0-003 CONT CONT XI  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Warrell et al.

Application No.: 10/759,293

Group Art Unit: 1616

Filed: January 16, 2004

Examiner: A. N. Pryor

For: PROCESS FOR PRODUCING ARSENIC  
TRIOXIDE FORMULATIONS AND  
METHODS FOR TREATING CANCER USING  
ARSENIC TRIOXIDE OR MELARSOPROL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)**


Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge Deposit Account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our Deposit Account No. 12-1095.

Dated: August 18, 2004

Respectfully submitted,

By *Shawn P. Foley*  
Shawn P. Foley  
Registration No.: 33,071  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 18, 2004

Signature:

*Shawn P. Foley*  
(Shawn P. Foley)

Docket No.:  
CELLTH 3.0-003 CONT CONT XI  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Warrell et al.

Application No.: 10/759,293

Group Art Unit: 1616

Filed: January 16, 2004

Examiner: A. N. Pryor

For: PROCESS FOR PRODUCING ARSENIC  
TRIOXIDE FORMULATIONS AND  
METHODS FOR TREATING CANCER USING  
ARSENIC TRIOXIDE OR MELARSOPROL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in United States Patent 6,723,351, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account

08/25/2004 EAREGAY1 00000022 121095 10759293

01 FC:1806 180.00 DA

Application No.: 10/759,293

Docket No.: CELLTH 3.0-003 CONT CONT XI

No. 12-1095.

Dated: August 18, 2004

Respectfully submitted,

By Shawn P. Foley  
Shawn P. Foley

Registration No.: 33,071

LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP

600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant

510383\_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/759,293
				Filing Date	January 16, 2004
				First Named Inventor	Raymond P. Warrell, Jr.
				Art Unit	1616
				Examiner Name	A. N. Pryor
Sheet	1	of	5	Attorney Docket Number	CELLTH 3.0-003 CONT CONT XI

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA**	US-132,275-B1	10-15-1872	Gettings	
	AB**	US-232,807	10-05-1886	Dennett	
	AC**	US-3,700,498	10-24-1972	Kanazawa et al.	
	AD**	US-4,497,780	02-05-1985	Barin et al.	
	AE**	US-5,759,837	06-02-1998	Kuhajda et al.	
	AF**	US-2002/0183385	12-05-2002	Ellison et al.	
	AG**	US-6,720,011	04-13-2004	Zhang, Ting-Dong	
	AH**	US-6,770,304	08-03-2004	Warrell et al.	
	AI**	US-2003/0099719	05/2003	Warrell et al.	
	AJ**	US-6,723,351	04-20-2004	Warrell et al.	
	AK**	US-6,773,792	05-11-2004	Lu	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	JP-51-88620	03-08-1976			
	BB	WO-95/01789	01-19-1995			
	BC	CN-1133725	10-23-1996			
	BD	CN-1131037	09-18-1996			
	BE	CN-1122700	05-22-1996			
	BF	CN-1081104	01-26-1994			
	BG	CN-1119113	03-27-1996			
	BH	CN-1061908	06-17-1992			
	BI	CN-1121807	05-08-1996			
	BJ	CN-1079391	12-15-1993			
	BK	WO-94/02103	02-03-1994			
	BL	FR-2 539 993	03-31-1994			
	BM	DE-43 17 331	12-01-1994			
	BN	WO-95/22336	08-24-1995			
	BO	LV-11667	06-20-1997			
	BP	WO-94/02108	02-03-1994			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† <sup>2</sup>
	CA	CUTLER et al., Article IV, American Journal of the Medical Sciences, pp. 74-84, January 1878	
	CB	FORKNER et al., "Arsenic as a therapeutic agent in chronic myelogeneous leukemia", Jour.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/759,293
				Filing Date	January 16, 2004
				First Named Inventor	Raymond P. Warrell, Jr.
				Art Unit	1616
				Examiner Name	A. N. Pryor
Sheet	2	of	5	Attorney Docket Number	CELLTH 3.0-003 CONT CONT XI

		A.M.A. 97(1):3-5, 1931	
	CC	STEPHENS, et al., "The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia", University of Rochester, pp. 1488-1502, 1936	
	CD	NEUBAUER, "Arsenical cancer: a review", Arsenic Committee of the Medical Research Council, pp. 192-251, 1947	
	CE	SHIBUYA, "Studies on experimental arsenious acid poisoning", Tokyo Jikeikai Ika Daigaku Zasshi, 86(4):653-675, 1971	
	CF	PORIES et al., "Trace elements that act to inhibit neoplastic growth", Annals of New York Academy of Sciences, 199:265-273, June 25, 1972	
	CG	MONFARDINI et al., "Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis", Cancer 31: 492-501, 1973	
	CH	KERKVLiet et al., "Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity", J. Environmental, Vol. 4, pp. 65-79, 1980.	
	CI	ISHINISHI, et al., "Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages", Fukuoka Acta Medicine, 71:27, 1980	
	CJ	Arsenic, Environmental Health Criteria, 18, Geneva: WHO, 1981	
	CK	CUZICK et al., "Medicinal Arsenic and Internal Malignancies", Br. J. Cancer, 45:904-911, 1982	
	CL	QI and BI, "Method for Removing As <sub>2</sub> O <sub>3</sub> from Realgar, Chung Yao Tung Pao, 8(5):21-22, 1983	
	CM	KASPER et al., "Hepatic Angiosarcoma and Bronchioloalveolar Carcinoma Induced by Fowler's Solution", JAMA 252(24):3407-3408, 1984	
	CN	ZHANG et al., "Clinical Study on the Treatment of Acute Promyelocytic Leukemia with Ai Ling #1", J. of Traditional Chinese and Western Medicine, Vol. 4, No. 1, p. 19, 1984.	
	CO	PERSHAGEN et al., "On the Pulmonary Tumorigenicity of Arsenic Trisulfide and Calcium Arsenate in Hamsters", Cancer Letters, 27:99-104, 1985	
	CP	SHIMOTSUURA et al., "Studies on the Antineoplastic Actions of As <sub>2</sub> O <sub>3</sub> ", Shikwa Gakuho, 86:1237-1253, 1986	
	CQ	YAMAMOTO et al., "Tumorigenicity of Inorganic Arsenic Compounds Following Intratracheal Installations to the Lungs of Hamsters", Int. J. Cancer 40:220-223, 1987	
	CR	LEE et al., "Induction of Gene Amplification by Arsenic", Science, 241: 79-81, 1988	
	CS	LI et al., "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma", Chinese J. Oncology, 10:61-62, 1988	
	CT	SUN, HONGDE et al., "32 Cases of Acute Early Granulocytic Leukemia Treated with Ai-Ling No. 1 in Combination with Chinese Medical Practice of Pattern Identification", Zhongguo Zhongxiyi Jiehe Zazhi, Vol. 12(3), 170-171, 1992	
	CU	PENG, ZHANG et al., "Treatment of Acute Promyelocyte Leukemia with Intravenous Arsenic Trioxide", Chinese Journal of Hematology, Vol. 17, Translation, February 1996	
	CV	Arsen (III)-Sulfid As <sub>2</sub> S <sub>2</sub> ", Gmelin's Arsenic, 8.sup.th Edition, 17:422-433, 1952	
	CW	Diarsendisulfid As <sub>2</sub> S <sub>2</sub> ", Gmelin's Arsenic, 8.sup.th Edition, 17:417-422, 1952	
	CX	Goodman & Gilman's "The Pharmacological Basis of Therapeutics", Ninth Edition, McGraw-Hill, Health Professions Division, pp. 1659-1662	
	CY	"Inorganic Arsenic Compounds Other Than Arsenic Health and Safety Guide", Health and Safety Guide No. 70," WHO, Geneva 1992	
	CZ	"Xionghuang, Realgar", Chinese Pharmacopoeia (I), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995	
	CA1	AKAO et al., "Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein", British J of Hematology, 102, 1055-1060, 1998 ©Blackwell Science Ltd.	
	CB1	ANDRE et al., "The PML and PML/RAR $\alpha$ Domains: From Autoimmunity to Molecular Oncology and From Retinoic Acid to Arsenic", Experimental Cell Research, 229:253-260, 1996 ©Academic Press, Inc. 1996	
	CC1	Chemical Abstract, 63-Pharmaceuticals 11:317, 111:219272j and 111:219276p, 1987-1991	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/759,293
				Filing Date	January 16, 2004
				First Named Inventor	Raymond P. Warrell, Jr.
				Art Unit	1616
				Examiner Name	A. N. Pryor
Sheet	3	of	5	Attorney Docket Number	CELLTH 3.0-003 CONT CONT XI

CD1	CHEN et al., "In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia: As <sub>2</sub> O <sub>3</sub> Induces NB <sub>4</sub> Cell Apoptosis with Down Regulation of Bcl-2 Expression and Modulation of PML-RAR $\alpha$ /PML proteins", Blood 88(3): 1052-1061, Aug. 1996. ©American Society of Hematology 1996
CE1	CHEN et al., "Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL):I. As <sub>2</sub> O <sub>3</sub> Exerts Dose-Dependent Dual Effects on APL Cells", Blood 89(9):3345-3353, 1997 ©The American Society of Hematology 1997
CF1	CHUNG et al., "Influence for Carcinoma Cell and Lymphatic Cell of Acetyl Arsonate", Yakhak Hoeji 40(5):599-607, 1996 (Abstract Only)
CG1	DE THE "L'oxyde d'arsenic: apres l'acide retinoique, un nouveau traitement cible dela leucemie aigue promyelocytaire" Medecine/Sciences, 13:867-71, 1997
CH1	Dictionary of Inorganic Compounds, vol. 1, Ac-C <sub>10</sub> , IC-0006667-IC-000671 (1992)
CI1	FLAMIGNI et al, "Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells", Cell Biochemistry and Function 7:213-217, 1989
CJ1	Fluka, 1995/96 Catalog: 152-153
CK1	GERMOLEC et al., "Arsenic Induces Overexpression of Growth Factors in Human Keratinocytes", Toxicology and Applied Pharmacology, 141:301-318, 1996 ©Academic Press, Inc., 1996
CL1	HUANG et al., 1995, "The Clinical Study of QINGDAI Tablet for Treating Acute Promyelocytic Leukemia", China Magazine of Hematology, 16(1):26
CM1	KONIG et al., "Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines", Blood 90(2):562-570, 1997. ©The American Society of Hematology 1997
CN1	KWONG et al., "Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia", Blood 89:3487-8, 1997
CO1	LU et al., "Effective treatment of AML-M3 (APL) and Their Remission Maintenance with Reaglar: A Pilot Clinical and Laboratory Study on 38 Patients", Blood, 90 (10 Suppl. 1, part 1):416A, #1849, 1997
CP1	LU et al., "Study of Reaglar in the Treatment of Acute Promyelocytic Leukemia (APL)-a pilot clinical and laboratory study on 32 Patients", China-Korea Medical Conference '97, 1997
CQ1	MERVIS, "Ancient Remedy Performs New Tricks", Science 273:578, 1996
CR1	NEUBAUER, "Arsenic Cancer: A Review", Arsenical Cancer, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947
CS1	REICHL et al., "Effect of Arsenic on Cellular Metabolism after Single or Repeated Injection in Guinea Pigs", Arch. Toxicol, Suppl. 13, p. 363-65, 1989
CT1	Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, pp. 1570-1580, 1990
CU1	SCHENK, Handbook of Preparative Inorganic Chemistry, 1:603, G. Brauer, Ed., Academic Press, New York, 2.sup.nd Edition, 1963
CV1	SHEN et al., "Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL):II Clinical Efficacy and Pharmacokinetics in Relapsed Patients", Blood 89(9):3354-3360, 1997 ©The American Society of Hematology 1997
CW1	SOIGNET et al., "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", J of Medicine 339:19, 1998. ©Massachusetts Medical Society 1998
CX1	TRELEAVEN et al., "Arsenic and Ayurveda", Leukemia and Lymphoma, 10:343-345, 1993
CY1	USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD p. 59, Nov. 1994.
CZ1	WANG et al., "Studies on Chemically Preventing Leukemia", Ghung Hua Chung Liu Tsa Chih, 11(3):207-210, 1989
CA2	XIANG et al., "60 Cases of Treating Acute Promyelocytic Leukemia by QINGDAI Tablet", Med. J. Chin. PLA 20(3):227-229, 1995

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/759,293	
			Filing Date	January 16, 2004	
			First Named Inventor	Raymond P. Warrell, Jr.	
			Art Unit	1616	
			Examiner Name	A. N. Pryor	
Sheet	4	of	5	Attorney Docket Number	CELLTH 3.0-003 CONT CONT XI

	CB2	YUAN et al., "Research on Traditional Methods for Purifying Realgar", Chung Yao Tung Pao, 13(8):23-26, 1988	
	CC2	YUAN et al., "Exploring Methods for Purifying Realgar", Chung Yao Tung Pao, 13(8):17-21, 1988	
	CD2	ZHANG et al., "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma," Chinese J. Oncology, 10:61-62, 1988	
	CE2	ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with "713": Clinical Observations and Study of Action Mode on 117 patients", J. Harbin Medical Univ. 29(3):243, 1995	
	CF2	ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide", Chinese J. of Hematology 17(2) 1996	
	CG2	ZHU et al., "Arsenic-induced PML Targeting Onto Nuclear Bodies: implications for the treatment of acute promyelocytic leukemia", Proc. Natl. Acad. Sci. 94:3978-3983, 1997, ©The National Academy of Sciences of the USA 1997	
	CH2	"Letter on Historical Facts Regarding the Development of Ai Ling No. 1 and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of Its Mechanism", Heilongjiang Branch of the Chinese Medical Association, Mar. 27, 1998.	
	CI2	WANG et al., "Arsenic Trioxide and Melarsprol Induced Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in PML and PNL-RAR $\alpha$ Independent Manner", Blood, 92(5):1497-1504, 1998	
	CJ2	USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD, p. 59, Nov. 1995.	
	CK2	WANG et al., "Arsenic and the Treatment of Leukemia", J Harbin Medical Univ., vol. 31, No. 5, Oct. 1997	
	CL2	SMORENBURG et al., "Randomized Cross-Over Evaluation of Body-Surface Area-Based Dosing Versus Flat-Fixed Dosing of Paclitaxel", J. Clin. Oncology, 21:197-202 (2003)	
	CM2	VOISEN et al., "Extrapolation of Animal Toxicity to Humans: Interspecies Comparisons in Drug Development", Regulatory Toxicology and Pharmacology, 12:107-116 (1990)	
	CN2	FREIRICH et al., "Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey and Man", Cancer Chemotherapy Reports, 50:219-244 (1966)	
	CO2	GURNEY, "How to Calculate the Dose of Chemotherapy", Brit. J. Cancer, 86:1297-1302 (2001)	
	CP2	SHARKEY et al., "Body Surface Area Estimation in Children Using Weight Alone: Application in Paediatric Oncology", Brit. J. Cancer, 85(1):23-8 (2001)	
	CQ2	AU et al., "Arsenic Trioxide in Comparison with Chemotherapy and Bone Marrow Transplantation for the Treatment of Relapsed Acute Promyelocytic Leukaemia", Annals of Oncology, 14:752-757 (2003)	
	CR2	ZHANG et al., "Pathologic, Cytogenetic and Molecular Assessment of Acute Promyelocytic Leukemia Patients Treated with Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> )", Modern Pathology; (2000); pp. 954-961	
	CS2	WESTERVELT et al.; "Sudden Death Among Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide"; Blood (2001); vol. 98, No. 2, pp. 266-271.	
	CT2	SOIGNET et al.; "United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia", Journal of Clinical Oncology, (2001), vol. 19, No. 18, pp. 3852-3880	
	CU2	WESERVELT et al., "Response and Toxicity Associated with Dose Escalation of Arsenic Trioxide in the Treatment of Resistant Acute Promyelocytic Leukemia", Blood 90 (10) (1997), p. 2496	
	CV2	SOIGNET et al., "Initial Clinical Study of a Novel Organic Arsenical, Melarsoprol, in Patients with Advanced Leukemia", Blood (W.B., Saunders, Philadelphia, PA), vol. 88, No. 10, p. 219A (ISSN: 0006-4971) (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/759,293
				Filing Date	January 16, 2004
				First Named Inventor	Raymond P. Warrell, Jr.
				Art Unit	1616
				Examiner Name	A. N. Pryor
Sheet	5	of	5	Attorney Docket Number	CELLTH 3.0-003 CONT CONT XI

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--